During the last decades, the term “drug delivery systems”(DDSs) has almost fully replaced
previously used terms, such as “dosage forms”, in an attempt to emphasize the importance …

A wide range of dry powder inhaler (DPI) devices are currently available on the market to
deliver drugs into lungs with a view to maximise drug delivery with low variability. DPIs also …

Dry powder inhalers (DPIs) are an important and increasingly investigated method of
modern therapy for a growing number of respiratory diseases. DPIs are a promising option …

Dry powder inhalers are a diverse family of devices that have emerged as a rapidly growing
segment of the respiratory therapeutics area. The forces that these devices must impart into …

Introduction: The number of pulmonary diseases that are effectively treated by aerosolized
medicine continues to grow. Areas covered: These diseases include chronic obstructive …

Dry powder inhalers (DPIs) are drug–device combination products where the complexity of
the formulation, its interaction with the device, and input from users play important roles in …

Dry powder inhalers (DPIs) have been available for delivering drugs to the lungs for over 30
years. In the last decade there has been a big increase in DPI development, resulting partly …

Pulmonary diseases affect more than 500 million people globally and are the leading
causes of death and disability worldwide [1]. A variety of therapeutic options, such as dry …

In the 50 years following the introduction of the first dry powder inhaler to the market, several
developments have occurred. Multiple-unit dose and multi-dose devices have been …

The current market for dry powder inhalers (DPIs) has over 20 devices in present use and at
least another 30 under development. Clinicians recognize that DPIs are a suitable …